FibroBiologics, Inc.
FBLGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The $11.4M market capitalization puts FBLG squarely in micro-cap range for its industry. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Market Cap
$11.4M
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
-0.53
EPS (TTM)
$-5.10
EPS (Fwd)
$-3.25
ROE
-660.1%
ROA
-95.8%
Cash
$3.5M
Total Debt
$1.5M
Free CF
-$8.4M
52W Change
-83.4%
Annual Financials
Cash vs Debt
Where FBLG stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FBLG finished 19.09% below its 150-day moving average ($2.41) and 41.09% below its 200-day moving average ($3.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBLG overbought or oversold?
At the September 3, 2026 close, FBLG's RSI(14) was 74.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
FibroBiologics, Inc. holds $3.5M in cash against $1.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -660.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.68 means FBLG is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing FBLG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.